Patent · US Active

Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases

US7378401B2 · kind B2 · utility

1Cited by

1References

13Claims

0Family size

Assignee

Heidelberg Pharma GmbH · DE

Inventors

Erwin Boehm · Ladenburg, DE
Michael Kulke · Ladenburg, DE
Eggert Stockfleth · Hanerau-Hademarschen, DE

Key dates

Filing date	Jul 14, 2006
Grant date	May 27, 2008
Priority date	—
Expiry date	Jan 19, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to the systemic administration of Fosfluridine Tidoxil, (5-fluorouridine)-5′-phosphoric acid (3-dodecylmercapto-2-decyloxy)propylester or a salt thereof, for the treatment of intraepithelial proliferative diseases such as actinic keratosis. The Fosfluridine Tidoxil can be systemically administered alone or in combination with topical treatment agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.